Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2011

View Archived Issues

Monash University develops dual-action PILs for fast delivery of active pharmaceutical ingredients

New hepcidin inhibitor exhibits antianemic effects in vivo

Phase II ARRY-520 trial in multiple myeloma yields encouraging results

Phase I study evaluates SCH-900776/cytarabine combination for leukemia

Oral rigosertib shows promise as a therapy for myelodysplastic syndrome

Asahi Kasei integrates two core operating companies

Celldex completes accrual in CDX-011 study

Astellas Pharma and UMN Pharma report phase I/II data on seasonal flu vaccine

Merck & Co. patents new hPDK1 inhibitors

Novel farnesyl pyrophosphate synthase inhibitors discovered in Canada

Janssen Pharmaceutica discloses novel estrogen-related receptor-alpha ligands

Enrollment begins in phase III trial of CF-101

NIAID begins trial of experimental chikungunya fever vaccine

Exelixis grants program license to Merck & Co.

Belgium-based company first to advance fatty acid FFA2 receptor antagonist to clinic

Novel fused imidazole derivatives prepared by Toa Eiyo

Abbott synthesizes new voltage-gated Ca(V)2.2 calcium channel antagonists

First patient with metastasized colorectal cancer treated in phase II trial of armed oncolytic virus

Phage Pharmaceuticals submits IND for first-in-class therapeutic

CytRx launches phase IIb study in advanced soft tissue sarcoma

Chelsea Therapeutics announces new data on droxidopa in fibromyalgia

Valeant Pharmaceuticals completes acquisition

Santarus files NDA for budesonide tablets

Trial of new patch for osteoporosis meets endpoints

XOMA commences new study of gevokizumab

MorphoSys commences clinical testing of MOR-103 for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...